Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Posters by Title

Type your Poster Title, then hit apply

Showing 1,267 results.

Thumbnail for Trends in Non-Hodgkin Lymphoma Incidence, Mortality, and Disease Burden Across Latin America from 1990 to 2023: A Global Burden of Disease Study

IBCL - 1325

Trends in Non-Hodgkin Lymphoma Incidence, Mortality, and Disease Burden Across Latin America from 1990 to 2023: A Global Burden of Disease Study

Renusri Ede

Poster Presenter: Renusri Ede

Thumbnail for Trends in Non-Hodgkin Lymphoma Mortality With Concurrent Septicemia in the United States, 1999-2025: A Population-Based CDC WONDER Analysis

MCL - 332

Trends in Non-Hodgkin Lymphoma Mortality With Concurrent Septicemia in the United States, 1999-2025: A Population-Based CDC WONDER Analysis

Ragav Vikraman Thiyagarajan

Poster Presenter: Ragav Vikraman Thiyagarajan

Previous 1...131 132 133 134 135 136 137...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Trends in Overall Survival in Multiple Myeloma by Age Group in the Era of Novel Therapies: A SEER 17 Population-Based Analysis (2000-2021)

MM - 1702

Trends in Overall Survival in Multiple Myeloma by Age Group in the Era of Novel Therapies: A SEER 17 Population-Based Analysis (2000-2021)

Fnu Muhibullah

Poster Presenter: Fnu Muhibullah

Thumbnail for Trends in Pneumonia-Related Mortality Among Patients With Hematological Malignancies in the United States, 1999-2020: A CDC WONDER Population-Based Analysis

AML - 1381

Trends in Pneumonia-Related Mortality Among Patients With Hematological Malignancies in the United States, 1999-2020: A CDC WONDER Population-Based Analysis

Rahul Anand

Poster Presenter: Rahul Anand

Thumbnail for Trends, Predictors, and Inpatient Burden of Neuropsychiatric Complications Following CAR-T Therapy: A National Inpatient Sample Analysis, 2017-2023

CT - 213

Trends, Predictors, and Inpatient Burden of Neuropsychiatric Complications Following CAR-T Therapy: A National Inpatient Sample Analysis, 2017-2023

Taimoor Nasir

Poster Presenter: Taimoor Nasir

Thumbnail for Trends, Predictors, and Outcomes of Do-Not-Resuscitate Status Among Adults Hospitalized With Acute Myeloid Leukemia: A National Inpatient Sample Analysis, 2016-2022

AML - 1160

Trends, Predictors, and Outcomes of Do-Not-Resuscitate Status Among Adults Hospitalized With Acute Myeloid Leukemia: A National Inpatient Sample Analysis, 2016-2022

Ameerdad Khan

Poster Presenter: Ameerdad Khan

$Thumbnail for Trial in Progress (IGNITE): A Phase 3, Multiregional, Open-Label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide (RTX-TMZ) in Relapsed/Refractory (R/R) Primary Central Nervous System Lymphoma (PCNSL)$

ABCL - 086

Trial in Progress (IGNITE): A Phase 3, Multiregional, Open-Label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide (RTX-TMZ) in Relapsed/Refractory (R/R) Primary Central Nervous System Lymphoma (PCNSL)

Lakshmi Nayak

Poster Presenter: Lakshmi Nayak

Thumbnail for Trial in Progress: A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naive Adult Patients With Myelofibrosis (MANIFEST-3)

MPN - 555

Trial in Progress: A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naive Adult Patients With Myelofibrosis (MANIFEST-3)

John Mascarenhas

Poster Presenter: John Mascarenhas

$Thumbnail for Trial in Progress: QUINTESSENTIAL-2, a Phase 3 Study of Arlocabtagene Autoleucel vs Standard of Care in Adult Patients With Relapsed/Refractory Multiple Myeloma Exposed to Lenalidomide$

MM - 1092

Trial in Progress: QUINTESSENTIAL-2, a Phase 3 Study of Arlocabtagene Autoleucel vs Standard of Care in Adult Patients With Relapsed/Refractory Multiple Myeloma Exposed to Lenalidomide

Eyal Lebel

Poster Presenter: Eyal Lebel

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors